Table 1.
Characteristics of the 85 participants who completed the COVID-19 specific questionnaire and provided clinical data
| Characteristic | N | |
|---|---|---|
| Site, n (%) | 85 | |
| - Victoria site 1 | 20 (23) | |
| - Victoria site 2 | 20 (23) | |
| - New South Wales (NSW) | 16 (19) | |
| - Western Australia (WA) | 29 (34) | |
| Age, years (mean ± SD, Range) | 85 | 66.1 ± 10.9; Range 29 – 87 |
| Gender, female n (%) | 85 | 53 (62) |
| Smoking status n (%) | 80 | |
| Never | 29 (36) | |
| Former | 49 (61) | |
| Current | 2 (3) | |
| BMI, kg/m2 (mean ± SD, Range) | 72 | 29.7 ± 6.0; Range 20.5 – 49.0 |
| ILD type n (%) | 82 | |
| - CTD-ILD | 19 (23) | |
| - HP | 6 (7) | |
| - IPF | 20 (24) | |
| - NSIP | 14 (17) | |
| - Sarcoidosis | 7 (9) | |
| - Scleroderma | 1 (1) | |
| - Unclassifiable ILD | 7 (9) | |
| - Other | 8 (10) | |
| Years since diagnosed with ILD, (mean ± SD, Range) | 79 | 5.4 ± 4.2; Range 0.5 – 25 |
| ILD medications use, yes, n (%) | 85 | 63 (74) (more than one option allowed) |
| Type | ||
| - Methotrexate | 5 (8) | |
| - Mycophenolate | 26 (41) | |
| - Nintedanib | 12 (19) | |
| - Pirfenidone | 8 (13) | |
| - Prednisolone | 17 (27) | |
| - Rituximab | 1 (2) | |
| Oxygen use – currently, yes, n (%) | 81 | 14 (17) |
| Pulmonary rehabilitation in last 12 months, Yes, n (%) | 80 | 17 (21) |
| Lung function assessments | ||
| 6MWT, ma (mean ± SD, Range) | 61 | 459.7 ± 132.6; Range 150 –774 |
| FVC %pred (mean ± SD, Range)a | 69 | 75.4 ± 16.7; Range 34 – 116 |
| DLCO %pred (mean ± SD, Range)a | 71 | 58.1 ± 17.0; Range 21 – 102 |
| Validated questionnaire scores | ||
| K-BILD transformed score, (mean ± SD, Range) | 85 | 55.8 ± 12.9; Range 27.2 – 100 |
| USCD-SOB score, (mean ± SD, Range) | 85 | 43.6 ± 25.0; Range 2 – 100 |
| Comorbidities | ||
| Main comorbidities | 85 | n (%) |
| - Autoimmune rheumatological disease | 12 (14%) | |
| - Chronic kidney disease | 11 (13%) | |
| - Diabetes mellitus | 9 (11%) | |
| - Haematological cancer (within last 5 years) | 0 (0%) | |
| - Heart disease | 5 (6%) | |
| - Non-haematological cancer (within last 12 months) | 1 (1%) | |
| Infections and hospitalization in 2020 | ||
| Tested for COVID-19 infection, yes n(%) | 85 | 35 (41) |
| - Number of positive tests | 0 (0) | |
| Lung infection, yes n(%) | 85 | 19 (22) |
| Hospital admissionb, yes n(%) | 85 | 24 (28) |
| Main reason for admission | ||
| - Infection | 8 (33) | |
| - Oxygen desaturation/dyspnoea | 5 (21) | |
| - Lung biopsy | 3 (13) | |
| - Kidney-related | 3 (13) | |
| - Other | 5 (21) | |
CTD-ILD Connective tissue disease-ILD, HP hypersensitive pneumonitis, IPF idiopathic pulmonary fibrosis, NSIP Nonspecific interstitial pneumonia, 6MWT 6 min walking test, FVC% pred forced vital capacity % predicted, DLCO% pred diffusing capacity for carbon monoxide % predicted, K-BILD The King’s Brief Interstitial Lung Disease, USCD-SOB The University of California San Diego Shortness of Breath
aRefers to last result prior to date when face-to-face clinic consultations changed to telehealth
bHospital admission defined as staying one or more nights